Drugs

Organigram Provides Corporate Update

Monday, November 11, 2019 - 11:30pm

Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the Company or Organigram), a leading licensed producer of cannabis, provided a corporate update today and announced details for its fiscal fourth quarter ended August 31, 2019 (Q4 2019) and full year 2019 conference call.

Key Points: 
  • Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the Company or Organigram), a leading licensed producer of cannabis, provided a corporate update today and announced details for its fiscal fourth quarter ended August 31, 2019 (Q4 2019) and full year 2019 conference call.
  • This is particularly relevant for LPs with strong distribution like Organigram which has sales in all 10 Canadian provinces.
  • Organigram submitted new product notifications to Health Canada for a vape pen portfolio and cannabis infused chocolates last month.
  • Organigram Holdings Inc. is a NASDAQ Global Select and TSX listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada.

Wet Age-Related Macular Degeneration Market by Product, by Distribution Channel, by Age Group, by Route of Administration, by End User, by Geography Global Market Size, Share, Development, Growth, and Demand Forecast, 2014-2024

Monday, November 11, 2019 - 10:20pm

Eylea, Lucentis, and Avastin are the drugs available worldwide for the treatment of wet AMD.

Key Points: 
  • Eylea, Lucentis, and Avastin are the drugs available worldwide for the treatment of wet AMD.
  • The major factors escalating the demand for this drug in the global wet age-related macular degeneration market are the rising prevalence of AMD.
  • In 2018, North America held the largest revenue share, amounting to nearly $3.0 billion, in the global wet age-related macular degeneration market.
  • Thus, the increasing government initiatives are boosting the wet age-related macular degeneration market growth in the APAC region.

Supernus Submits New Drug Application for SPN-812 for the Treatment of ADHD

Monday, November 11, 2019 - 9:15pm

SPN-812 is a well differentiated product candidate that, if approved by the FDA, can become a unique multi-symptom treatment option for many patients with ADHD.

Key Points: 
  • SPN-812 is a well differentiated product candidate that, if approved by the FDA, can become a unique multi-symptom treatment option for many patients with ADHD.
  • In addition, we announced last week that we initiated a Phase III program to study SPN-812 in the adult ADHD patient population.
  • SPN-812 is a serotonin norepinephrine modulating agent (SNMA) that Supernus is developing as a novel non-stimulant for the treatment of ADHD.
  • Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Lipocine Inc. - LPCN

Monday, November 11, 2019 - 6:44pm

NEW YORK, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Lipocine Inc. (Lipocine or the Company) (NASDAQ: LPCN).

Key Points: 
  • NEW YORK, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Lipocine Inc. (Lipocine or the Company) (NASDAQ: LPCN).
  • Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext.
  • Lipocine advised investors, inter alia, that [t]he CRL identified one deficiency stating the efficacy trial did not meet the three secondary endpoints for maximal testosterone concentrations.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

Hua Medicine’s Pivotal Phase III Monotherapy Trial of Dorzagliatin, a Dual-Acting Glucokinase Modulator, Achieves Primary Efficacy Endpoint in Patients with Type 2 Diabetes

Monday, November 11, 2019 - 4:00pm

The trial achieved its primary efficacy endpoint by demonstrating a statistically significant reduction in HbA1c levels over placebo during the first 24 weeks of the trial.

Key Points: 
  • The trial achieved its primary efficacy endpoint by demonstrating a statistically significant reduction in HbA1c levels over placebo during the first 24 weeks of the trial.
  • Our Phase III trial HMM302 [NCT03141073] targets patients who have failed metformin treatment and has recently completed enrollment.
  • HMM0301 [NCT03173391] is a randomized, double-blind, placebo-controlled Phase III study in 463 drug nave type 2 diabetes patients.
  • 1 Defined as less than 3.0 mmol/liter per the American Diabetes Association Standards of Medical Care in Diabetes 2019.

Emerald Organic Products to Acquire Vending Machine Company

Monday, November 11, 2019 - 3:24pm

Holbrook, New York, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Emerald Organic Products, Inc. ( OTC:EMOR ) (Emerald or the Company), a diversified cannabidiol (CBD) products company, is pleased to announce that the Company has signed an agreement to acquire a controlling 51 percent stake in Bezalels Jewelry, Inc. (Bezalels), a vending machine manufacturing and distributing company, which will offer the Company accretive opportunities for CBD vending and much more.

Key Points: 
  • Holbrook, New York, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Emerald Organic Products, Inc. ( OTC:EMOR ) (Emerald or the Company), a diversified cannabidiol (CBD) products company, is pleased to announce that the Company has signed an agreement to acquire a controlling 51 percent stake in Bezalels Jewelry, Inc. (Bezalels), a vending machine manufacturing and distributing company, which will offer the Company accretive opportunities for CBD vending and much more.
  • Emerald Organic Products all stock transaction with Bezalels will allow Emerald to immediately begin deploying and offering a Patent protected unique vending machine in select markets, commented Ian Parker, Chief Executive Officer and Executive Chairman of Emerald Organic Products, Inc.
  • Emerald Organic Products is known as the industry leader for CBD-infused product development through its Pura Vida brand, said Bezalels Jewelry, Inc. CEO Yuen Vincent Mao.
  • We look forward to leveraging our highly secure vending machine technology to expand Emeralds high-margin distribution of its Pura Vida CBD products in airports, convenience stores, gas stations, gyms, and more.

European Online Pharmacy (E-Pharma) Market Insights, Trends & Forecast Report 2019-2023 Featuring Zur Rose Group, Shop Apotheke Europe, Medikamente-per-klick, Apotea and Apotal - ResearchAndMarkets.com

Monday, November 11, 2019 - 3:12pm

The "European Online Pharmacy (E-Pharma) Market: Insights, Trends & Forecast (2019-2023)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "European Online Pharmacy (E-Pharma) Market: Insights, Trends & Forecast (2019-2023)" report has been added to ResearchAndMarkets.com's offering.
  • The European online pharmacy market is estimated to reach US$10.88 billion in 2023, growing at a CAGR of 4.20% for the period spanning from 2019 to 2023.
  • The European online pharmacy market is broadly segmented into two types which are online over-the-counter drugs and online prescription drugs.
  • The report provides a comprehensive analysis of the European online pharma market, segmented into online over-the-counter drugs and online prescription drugs.

Moreover, the same segment of pacemakers market is also expected to witness growth in its demand at the fastest CAGR of 8.2% from 2019 to 2027

Monday, November 11, 2019 - 3:30pm

On the other hand, continuous development in pacemakers' technology is likely to be a prevalent trend in the market.

Key Points: 
  • On the other hand, continuous development in pacemakers' technology is likely to be a prevalent trend in the market.
  • The North America pacemakers market on the basis of route of administration is segmented in to oral, transmucosal, injectable, topical, implantable and ocular.
  • In 2018, the oral segment held the largest market share of 50.2% of the pacemakers market, by route of administration.
  • Moreover, the same segment of pacemakers market is also expected to witness growth in its demand at the fastest CAGR of 8.2% from 2019 to 2027.

Cocrystal Pharma Presents Positive Data from U.S. Phase 2a Study of CC-31244 Demonstrating Ability to Identify Patients More Likely to Respond to Ultrashort Treatment of HCV

Monday, November 11, 2019 - 1:35pm

Phase 2a study evaluating CC-31244 and sofosbuvir/velpatasvir (Epclusa) for the ultrashort treatment of HCV infected individuals.

Key Points: 
  • Phase 2a study evaluating CC-31244 and sofosbuvir/velpatasvir (Epclusa) for the ultrashort treatment of HCV infected individuals.
  • Phase 2a trial, on Sunday November 10, 2019 and is available on the Companys website here .
  • Phase 2a study that were presented this past weekend at the AASLD 2019 Liver Meeting.
  • Phase 2a study is an open-label study designed to evaluate the safety, tolerability, and preliminary efficacy of CC-31244 with Epclusa in 12 subjects with treatment-nave HCV genotype 1.

cbdMD Announces Preliminary Fourth Quarter Record Net Sales

Monday, November 11, 2019 - 11:45am

cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD.PR.A), a nationally recognized consumer cannabidiol (CBD) brand, announced today preliminary unaudited net sales for the fourth quarter of fiscal 2019 which ended September 30, 2019.

Key Points: 
  • cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD.PR.A), a nationally recognized consumer cannabidiol (CBD) brand, announced today preliminary unaudited net sales for the fourth quarter of fiscal 2019 which ended September 30, 2019.
    cbdMDs unaudited net sales were $9.5 million for our last quarter of fiscal 2019, which was an increase of over 67% from our March 2019 quarter, which was our brands first full publicly reported fiscal quarter following the closing of the acquisition of the brand in December 2018.
  • We are very optimistic that our fiscal 2020 results will be another record growth year for cbdMD, said Martin Sumichrast, Chairman and co-CEO of cbdMD, Inc.
  • The quarterly net sales results presented in this release are not based upon our audited financial consolidated statements which will appear in our Annual Report on Form 10-K for the fiscal year ended September 30, 2019 are preliminary and may change.
  • cbdMD has one of the largest rosters of professional sports athletes who are part of Team cbdMD.